{"id":2216,"date":"2012-09-01T12:02:00","date_gmt":"2012-09-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/tiotropiumbromid-bei-asthma"},"modified":"2012-09-01T12:02:00","modified_gmt":"2012-09-01T10:02:00","slug":"tiotropiumbromid-bei-asthma","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/tiotropiumbromid-bei-asthma","title":{"rendered":"Tiotropiumbromid bei Asthma?"},"content":{"rendered":"<p>Die Anticholinergika Tiotropiumbromid (Spiriva\u00ae) und Ipratropiumbromid (Atrovent\u00ae, Itrop\u00ae) sind zur Bronchodilatation bei Chronisch obstruktiver Lungenerkrankung (COPD) eingef\u00fchrt neben Salmeterol (Aeromax\u00ae, Serevent\u00ae) und Formoterol (Foradil\u00ae u.a. und Generika) und gegebenenfalls Theophyllin (Afolinum\u00ae u.a., Generika) und Roflumilast (Daxas\u00ae; 1, 2). Im Fazit einer Nutzenbewertung von Tiotropium (Tio) schreibt das Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Anticholinergika Tiotropiumbromid (Spiriva\u00ae) und Ipratropiumbromid (Atrovent\u00ae, Itrop\u00ae) sind zur Bronchodilatation bei Chronisch obstruktiver Lungenerkrankung (COPD) eingef\u00fchrt neben Salmeterol (Aeromax\u00ae, Serevent\u00ae) und Formoterol (Foradil\u00ae u.a. und Generika) und gegebenenfalls Theophyllin (Afolinum\u00ae u.a., Generika) und Roflumilast (Daxas\u00ae; 1, 2). Im Fazit einer Nutzenbewertung von Tiotropium (Tio) schreibt das Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[470,467,4090,774],"class_list":["post-2216","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-asthma","tag-asthma-bronchiale","tag-tiotropium","tag-tiotropiumbromid"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2216"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2216\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}